Amedisys Inc (NASDAQ:AMED) Expected to Post Quarterly Sales of $494.57 Million

Wall Street brokerages expect Amedisys Inc (NASDAQ:AMED) to report sales of $494.57 million for the current quarter, according to Zacks. Seven analysts have issued estimates for Amedisys’ earnings, with the highest sales estimate coming in at $499.50 million and the lowest estimate coming in at $490.00 million. Amedisys reported sales of $417.34 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.5%. The business is scheduled to report its next quarterly earnings results after the market closes on Tuesday, October 29th.

On average, analysts expect that Amedisys will report full year sales of $1.97 billion for the current financial year, with estimates ranging from $1.96 billion to $1.98 billion. For the next fiscal year, analysts forecast that the company will post sales of $2.10 billion, with estimates ranging from $2.04 billion to $2.16 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Amedisys.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 31st. The health services provider reported $1.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.97 by $0.24. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The firm had revenue of $492.98 million during the quarter, compared to analyst estimates of $489.66 million. During the same period in the prior year, the company posted $1.00 earnings per share. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year.

Several research analysts have issued reports on the company. Raymond James increased their price objective on Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a research note on Monday, July 15th. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. ValuEngine cut Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, September 26th. Oppenheimer increased their target price on Amedisys from $140.00 to $150.00 in a report on Thursday, August 1st. Finally, Barclays increased their target price on Amedisys from $120.00 to $125.00 and gave the stock an “equal weight” rating in a report on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $141.51.

Amedisys stock traded up $0.62 during mid-day trading on Friday, hitting $135.26. 154,382 shares of the company were exchanged, compared to its average volume of 381,439. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.58. The business has a fifty day moving average of $130.59 and a 200 day moving average of $124.87. Amedisys has a 1-year low of $97.38 and a 1-year high of $141.98. The company has a market capitalization of $4.26 billion, a PE ratio of 37.26, a price-to-earnings-growth ratio of 1.97 and a beta of 1.44.

In related news, insider Michael Paul North sold 10,067 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $130.00, for a total value of $1,308,710.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott G. Ginn sold 4,871 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $132.06, for a total value of $643,264.26. The disclosure for this sale can be found here. Insiders have sold 21,916 shares of company stock worth $2,878,098 in the last 90 days. Company insiders own 2.90% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Rehmann Capital Advisory Group bought a new position in Amedisys in the second quarter valued at about $31,000. CWM LLC boosted its holdings in Amedisys by 482.2% in the second quarter. CWM LLC now owns 262 shares of the health services provider’s stock valued at $32,000 after acquiring an additional 217 shares during the last quarter. Tompkins Financial Corp bought a new position in Amedisys in the second quarter valued at about $37,000. Point72 Asset Management L.P. bought a new position in Amedisys in the second quarter valued at about $49,000. Finally, Maverick Capital Ltd. bought a new position in Amedisys in the second quarter valued at about $54,000. Institutional investors and hedge funds own 88.57% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Read More: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.